VEII yields 400000.00% · PFE yields 6.13%● Live data
📍 VEII pulled ahead of the other in Year 1
Combined, VEII + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VEII + PFE for your $10,000?
Value Exchange International, Inc. provides customer-centric technology solutions to the retail industries in the People's Republic of China, Hong Kong, Malaysia, and the Philippines. The company offers credit and debit card processing services to multinational retailers. It also provides systems maintenance and related services, including software patches and software code revisions; installing, testing, and implementing of software; training of customer personnel for the use of software; and technical support for software systems. In addition, the company offers system installation and implementation services comprising project planning, system analysis and design, hardware and consumables selection advice and sales, and system hardware maintenance services; and systems development and integration services. Further, it engages in the software development; trading and servicing of computer hardware and software; IT service call-center activities; and marketing, sale, and maintenance of point of sale (POS) software under the edgePOS brand, as well as sale of third party POS software programs. The company was formerly known as Sino Payments, Inc. and changed its name to Value Exchange International, Inc. in December 2017. Value Exchange International, Inc. was incorporated in 2007 and is based in Sha Tin, Hong Kong.
Full VEII Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.